Program
zeprumetostat
Also written as “SHR2554”, “TLN-254” and “SHR2554 Tablets”.
Its studies are mostly in Lymphoma · Neoplasms · Prostatic Neoplasms · Carcinoma, Non-Small-Cell Lung · Stomach Neoplasms, led by 2 companies.
Drug pageZeprumetostat: every studyAll 39 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jiangsu HengRui Medicine | 166 open or running | phase 3since Nov 5, 2023 | Jul 10, 2018 | Apr 2027phase 2 · NCT06368167 |
| Treeline Biosciencesits history only | 11 open or running | phase 1since Dec 10, 2024 | Dec 10, 2024 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Jiangsu HengRui Medicine only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Before these, 2 studies since Jul 10, 2018.
- Apr 1, 2020Phase 1 study in Healthy Adult SubjectsNCT04335266 · 20 enrolled · China
- Sep 24, 2020Phase 1 study in HealthyNCT04577885 · 18 enrolled · China
- Oct 27, 2020Phase 1 study in Healthy Adult SubjectsNCT04627129 · 18 enrolled · China
- Sep 9, 2021Phase 1 study in LymphomaNCT05049083 · 28 enrolled · China
- Oct 20, 2022Phase 1 study in NeoplasmsNCT05592262 · 20 enrolled · China
- Dec 15, 2022Phase 1 study in NeoplasmsNCT05661591 · 18 enrolled · China
- Aug 20, 2023Phase 1 study in LymphomaNCT06010680 · 6 enrolled · China
- Oct 17, 2023Phase 1 study in NeoplasmsNCT06093945 · 20 enrolled · China
- Nov 5, 2023Phase 3 study in RecurrenceNCT06122389 · 130 planned · China
- Dec 8, 2023Phase 2 study in Lymphoma, T-Cell, PeripheralNCT06173999 · 100 planned · China
- Apr 11, 2024Phase 2 study in Lymphoma, FollicularNCT06368167 · 105 planned · China
- Aug 11, 2024Named zeprumetostatINNProposed as its International Nonproprietary Name in WHO's List 131 · before, SHR2554, TLN-254
- Jul 29, 2025Phase 2 study in Stomach NeoplasmsNCT07102901 · 351 planned · China
- Sep 9, 2025Phase 2 study in Carcinoma, Non-Small-Cell LungNCT07175220 · 200 planned · China
- Nov 13, 2025Phase 2 study in Prostatic NeoplasmsNCT07230106 · 218 planned · China
Ahead
- Apr 2027Primary completion: phase 2 study in Lymphoma, FollicularNCT06368167
- Dec 2027Primary completion: phase 2 study in Stomach NeoplasmsNCT07102901
- Oct 2028Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT07175220
- Dec 2028Primary completion: phase 2 study in Prostatic NeoplasmsNCT07230106
TargetBeta
“An orally available selective inhibitor of the histone lysine methyltransferase (HMT) enhancer of zeste homolog 2 (EZH2), ”NCIt, by rule
Other programs on EZH2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| mevrometostat | Pfizer | phase 3 | 7 |
| TR115rule | tarapeutics-science-inc | phase 3 | 3 |
| tulmimetostat | Novartis | phase 2 | 3 |
| EZH1/2 Inhibitor HH2853rule | Haihe Biopharma | phase 2 | 2 |
| valemetostatrule | Daiichi Sankyo | phase 1 | 1 |
Studies
All 16 Jiangsu HengRui Medicine leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07230106Prostatic Neoplasms · China | 2 | Recruiting | Dec 2028 | 218 |
| NCT07175220Carcinoma, Non-Small-Cell Lung · China | 2 | Recruiting | Oct 2028 | 200 |
| NCT07102901Stomach Neoplasms · China | 2 | Recruiting | Dec 2027 | 351 |
| NCT06368167Lymphoma, Follicular · China | 2 | Not yet recruiting | Apr 2027 | 105 |
| NCT06173999Lymphoma, T-Cell, Peripheral · China | 2 | Recruiting | Dec 31, 2025 | 100 |
| NCT06122389Recurrence · China | 3 | Recruiting | May 2026 | 130 |
| NCT06093945Neoplasms · China | 1 | Completed | Nov 29, 2023 | 20 |
| NCT06010680Lymphoma · China | 1 | Completed | Nov 27, 2023 | 6 |
| NCT05661591Neoplasms · China | 1 | Completed | Mar 31, 2023 | 18 |
| NCT05592262Neoplasms · China | 1 | Completed | Dec 14, 2022 | 20 |
| NCT05049083Lymphoma · China | 1 | UNKNOWN | Jan 6, 2022 | 28 |
| NCT04627129Healthy Adult Subjects · China | 1 | Completed | Oct 1, 2020 | 18 |
| NCT04577885Healthy · China | 1 | Completed | Aug 30, 2020 | 18 |
| NCT04335266Healthy Adult Subjects · China | 1 | Completed | Sep 9, 2019 | 20 |
| NCT03741712Prostatic Neoplasms · China | 2 | Terminated | Sep 30, 2019 | 9 |
| NCT03603951Recurrence · China | 1 | UNKNOWN | Feb 14, 2026 | 272 |
How it is read
Names in the registry
- “SHR2554”, 6 entries
- “TLN-254”, 2 entries
- “SHR2554 Tablets”, 2 entries
- “SHR2554 Tablet”, 1 entry
- “SHR2554; Chidamide analog tablets”, 1 entry
Codes read as this program: SHR2554.
Conditions, from the studies’ own filings
- Lymphoma, 3 studies
- Neoplasms, 3 studies
- Prostatic Neoplasms, 2 studies
- Carcinoma, Non-Small-Cell Lung, 1 study
- Stomach Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.